Hyperion Therapeutics signs interim agreement with Clal Biotechnology Industries
M2 - Tue Oct 07, 6:32AM CDT
Biopharmaceutical company Hyperion Therapeutics (NasdaqGS :HPTX) announced on Tuesday that it has signed an interim agreement to resolve its disputes with Clal Biotechnology Industries (Tel Aviv :CBI.TA).
HPTX: 26.83 (-0.05)
Avraham Pharmaceuticals Raises $4.5 Million in Additional Investment Led by Yissum
Business Wire - Wed Sep 17, 6:58AM CDT
Avraham Pharmaceuticals Ltd. announced today that Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissum's biotech holdings company and the Technion Research and Development Foundation Ltd. (TRDF) and others invested an additional $4.5 million in the Company. Following the current investment round, Yissum and Integra Holdings will now hold 46% of the shares of Avraham Pharmaceuticals.